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Introduction
The tumor vasculature represents a promising target for cancer therapy. Vascular disrupting agents (VDAs) are a new class of potential antitumor drugs that selectively destroy the established tumor vasculature, shut down blood supply, deprive tumors of oxygen and nutrition, and cause extensive tumor necrosis (Chaplin & Dougherty, 1999; Lippert, 2007; Philip E. Thorpe, 2003) . There are two types of VDAs: small molecules and ligand-directed agents. Currently, most small molecule VDAs are tubulin inhibitors, such as combretastatin A-4P and ZD6126; the remainder are synthetic flavonoids, including flavone acetic acid (FAA) and DMXAA (Cai, 2007) .
5, 6-Dimethylxanthenone-4-acetic acid (DMXAA), also known as ASA404, is a FAA derivative that acts as an effective VDA. DMXAA causes a rapid and remarkable collapse in blood flow within 30 min after administration and leads to complete vascular shutdown later (Tozer et al, 2005) . Clinical studies have confirmed the anti-vascular effect, demonstrating an increase in tumor vascular permeability (Baguley et al, 2005) , changes in tumor perfusion (Murata et al, 2001) , and increased plasma concentrations of the serotonin metabolite 5-hydroxyindole acetic acid (Zhao L, 2002) . DMXAA is thought to exert its antitumor effects through both induction of apoptosis in tumor vascular endothelial cells (Ching et al, 2002a) and an indirect vascular effect involving production of a spectrum of cytokines and chemokines, including tumor necrosis factor-α (TNF-α) (Wang, 2004) , interferon-β (Shirey et al, 2011) ,interferon-inducible protein 10 (Cao Z, 2001) , and inducible nitric oxide synthase (iNOS) (Peng et al, 2011) . It has been reported that TNF-α is an important cytokine involved in mediating the antitumor effects of DMXAA (Ching LM, 1999 ) .
In situ hybridization studies of the murine Colon 38 tumor have shown that the extent of DMXAA-induced TNF-α synthesis is greater in tumors than that in the spleen, JPET # 191635 5 liver, or serum (Joseph WR 1999) . More importantly, previous results have demonstrated that mice lacking genes for TNF or TNF receptor-1 (Ching LM, 1999 ) exhibit a partially diminished tumor-regression response to DMXAA treatment.
DMXAA completed Phase I clinical trials in New Zealand and the United Kingdom, showing good tolerance (Rustin et al, 2003) . A Phase II clinical trial that tested DMXAA in combination with carboplatin and paclitaxel against non-small-cell lung cancer demonstrated a greater tumor response rate, a reduction in median time to tumor progression, and improved median survival (McKeage et al, 2009 ). However, a Phase III trial in 2010 showed no survival benefit of DMXAA combination therapy in patients with late-stage lung cancer. Given the effectiveness of DMXAA as a VDA, efforts to elucidate novel mechanisms of action of this agent and explore new administration approaches remain of paramount importance.
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine kinases involved in regulating a variety of cellular processes, including inflammation, cell growth and survival, and cellular differentiation (Karin & Chang, 2001 ). Three kinds of MAPKs have been identified: extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK. Of these, p38 MAPK appears to be involved in the production of cytokines by stimulated monocytes (Saklatvala, 2004) .
Inhibitors of p38 MAPK have been reported to block lipopolysaccharide-induced TNF-α production at both transcriptional (Manthey CL, 1998) and post-transcriptional (Young P, 1993) levels. p38 MAPK has also been shown to regulate actin microfilament dynamics via activation of MAPKAP (mitogen-activated protein kinase-activated protein) kinase 2/3 and phosphorylation of HSP27 (heat-shock protein 27) (Freshney et al, 1994; Rouse et al, 1994) in endothelial cells, resulting in JPET # 191635 6 stress fiber formation. Previous research has also provided evidence that p38 MAPK is necessary for combretastatin A4-induced endothelial cell blebbing (Kanthou & Tozer, 2002) and involved in the action of DMXAA (Zhao et al, 2007) .Very recently, it has been reported that MAPKs, especially p38 MAPK, play an important role in regulation of both TNF-a and IL-6 protein production induced by DMXAA in murine macrophages at the post-transcriptional level (Sun et al, 2011) . However, the direct roles of p38 MAPK in the DMXAA's in vivo anti-tumor activity, especially in the DMXAA-induced tumor vascular shut-down, is still not known.
In this study, we examined the role of p38 MAPK in the antitumor activity of DMXAA. In vitro, p38 MAPK was critically involved in DMXAA-induced actin cytoskeleton reorganization in human umbilical vein endothelial cells (HUVECs) and TNF-α production in macrophages. Consistent with this, in vivo inhibition of p38 MAPK significantly attenuated the tumor vascular shutdown by inhibiting the rapid DMXAA-induced endothelial cell cytoskeleton reorganization and subsequent TNF-α production. These results demonstrate that p38 MAPK is required for DMXAAinduced disruption of the tumor vasculature. JPET # 191635 8 HUVECs were plated in 6-well plates preincubated with 1% gelatin. Cells were grown for at least 24 hours before treatment. Photographs were taken using an Olympus fluorescence microscope. For quantitation of cell area, images were acquired from randomly selected areas of slides and then analyzed using Image Pro Plus 6.0 software (Media Cybernetics, Silver Spring, Maryland, USA).
F-actin staining
HUVECs were plated on glass cover slips 24 hours before performing experiments.
Following DMXAA treatment with or without inhibitors, as indicated in the text, cells were washed with phosphate-buffered saline (PBS) and then fixed for 20 minutes in 4% paraformaldehyde/PBS. Alexa Fluor 594-conjugated phalloidin (diluted 1:100 in 2% BSA/PBS) and 4', 6-diamidino-2-phenylindole (0.1 μ g/ml) were used to stain F-actin and nuclei, respectively. After extensive washes, cells were mounted and visualized by fluorescence microscopy.
Western blotting
After drug treatment, cells were washed twice with ice-cold PBS and lysed in sodium dodecyl sulfate (SDS) sample buffer. Cell lysates containing equal amounts of protein were separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes. After blocking in 5% non-fat milk in Tris-buffered saline with 0.1% Tween-20, membranes were incubated at 4°C overnight with the appropriate primary antibodies and then exposed to secondary antibodies for 2 hours at room temperature. Immunoreactive proteins were visualized using an enhanced chemiluminescence system (Pierce Chemical, Rockford, IL, USA).
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TNF-α determination
Removed tumor tissues were homogenized in culture medium using a tissue homogenizer. The homogenates were centrifuged (2000 x g, 30 min, 4°C) and supernatants were collected and kept at -70°C until use. TNF-α was assayed using a TNF-α mouse enzyme-linked immunosorbent assay (ELISA) Kit according to the manufacturer's directions (Invitrogen, CA, USA).
RNA interference
Ana-1 cells were transfected with small interfering RNA (siRNA) duplexes (100 nM) against p38 using the TurboFect siRNA transfection reagent (Fermentas, St.
Leon-Roth, Germany), as described by the manufacturer. The cells were then allowed to recover for 72 hours before stimulation. The siRNA sequence targeting mouse p38α (NM_011951), synthesized by Genepharma (Shanghai, China), spans nucleotides 481-499 (target sequence, 5′-GAC TGT GAG CTC AAG ATT C-3′) and is specific for mouse p38 MAPK based on a BLAST search of the NCBI database. The sense p38-siRNA sequence was 5′-GAC UGU GAG CUC AAG AUU Ctt-3′ and the antisense sequence was 5′-GAA UCU UGA GCU CAC AGU Ctt-3′. Negative control siRNA sequences were 5′-UUC UCC GAA GGU GUC ACG Utt-3′ (sense) and 5′
-ACG UGA CAC GUU CGG AGA Att-3′ (antisense).
Mice and tumors
Six-to-eight-week-old female C57 mice weighing 16-18 g were purchased from
Shanghai SLAC Laboratory Animal Co. Ltd (Shanghai, China) and raised under 
Blood perfusion determination
The perfused vasculature in Lewis lung tumors was identified by intravenous injection of 100 μ l (8 mg/ml) of Hoechst 33342 dye into the tail vein (Smith et al, 1988; Trotter et al, 1990) . One minute after dye injection, mice were euthanized by cervical dislocation. Tumors were quickly removed and rapidly frozen over liquid nitrogen for subsequent sectioning (6-μm cryosections). Using this method, perfused blood vessels could be visualized by the surrounding halo of fluorescent, Hoechst 33342-labeled cells. Images were captured using a fluorescence microscope and analyzed using Image Pro Plus 6.0 software.
Assessment of hemorrhagic necrosis
Tumors were removed 24 hours after treatment with or without DMXAA and fixed in 10% formalin. Fixed tumors were then embedded in paraffin and sectioned. Sections were stained with hematoxylin and eosin. Photographs were taken using an inverted microscope. For quantitation of necrotic area, images were acquired from randomly selected areas of slides and then analyzed using Image Pro Plus 6.0 software.
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Statistical analysis
The results are expressed as means ± SEMs. Paired Student's t-tests were used to test for significance, where indicated. MAPK is required for the DMXAA-induced actin cytoskeleton reorganization that leads to changes in HUVEC morphology.
Results
As expected, DMXAA significantly stimulated the activation of p38 MAPK, but not ERK1/2, as early as 5 minutes in HUVECs ( Figure 1D ). Myosin light chain (MLC), which regulates actin stress fiber assembly (Smith et al, 1988) , was also phosphorylated at Thr-18 and Ser-19 after treatment with DMXAA for 15 minutes ( Figure 1D ). Furthermore, pretreatment with the p38 MAPK inhibitor SB202190
significantly inhibited DMXAA-induced phosphorylation of both p38 MAPK and MLC ( Figure 1E ), suggesting that DMXAA-stimulated p38 MAPK activation is upstream of MLC phosphorylation in HUVECs.
p38 MAPK activation is essential for TNF-α production in Ana-1 murine macrophages following DMXAA exposure.
Several studies have shown that TNF-α, secreted from macrophages, is an important regulator of the antitumor activity of DMXAA. Thus, we tested whether p38 MPAK was also activated in murine Ana-1 macrophages during DMXAA treatment. As shown in Figure 2A , p38 MAPK activation in Ana-1 cells was observed as early as 30 minutes after DMXAA treatment ( Figure 2A ). MAPKAPK-2, a downstream effector of p38 MAPK, was also phosphorylated 30 minutes after exposure to DMXAA (Figure 2A ). These results raise the possibility that DMXAA stimulation of p38 MAPK activation is not cell-type specific. In addition, ERK1/2 JPET # 191635 13 phosphorylation was also slightly increased after DMXAA treatment for 30 min in Ana-1 macrophages ( Figure 2A ).
To explore whether DMXAA-induced p38 MAPK activation was related to TNF-α production in Ana-1 cells, we pretreated cells with the p38 MAPK inhibitor SB202190 before exposure to DMXAA. Figure 2B shows that DMXAA-stimulated TNF-α production was significantly reduced (~60%) by SB202190 pretreatment for 30 minutes ( Figure 2B ), and was sligtly affected by pretreatment with the ERK1/2 inhibitor PD0325901 (~20%), but was unaffected by the JNK inhibitor SP600125
(data not shown), suggesting that MAPKs, especially p38 MAPK, participate in DMXAA-induced TNF-α production in Ana-1 cells.
To confirm the role of p38 MAPK in TNF-α production, we used a more specific approach, employing siRNA against p38 MAPK. As shown in Figure 2C , transfection of Ana-1 cells with p38 siRNA significantly reduced p38 MAPK protein expression as well as DMXAA-induced TNF-α production, confirming that p38 MAPK is a critical mediator of DMXAA-induced TNF-α production in macrophages.
p38 MAPK activation is critically involved in DMXAA-induced tumor vascular disruption in vivo.
The role of p38 MAPK in mediating DMXAA-induced antitumor activity was examined in vivo using an established Lewis lung cancer model in C57 mice. Tumor fragments were implanted in C57 mice and allowed to grow to 10 mm in diameter before DMXAA administration. Consistent with previous reports (Joseph et al, 1999) , treatment of C57 mice with DMXAA at a dose of 20 mg/kg induced a time-dependent production of intratumoral TNF-α, which increased from undetectable levels at 30 minutes and 2 hours to reach significant levels at 4 hours ( Figure 3A ). In contrast, This article has not been copyedited and formatted. The final version may differ from this version. Figure 6A and B, extensive necrotic areas within tumors were observed in mice treated with DMXAA for 24 hours; in contrast, untreated mice showed large areas of viable cells without significant necrosis. SB202190 treatment alone had no effect on cell viability in tumor tissues; however, it remarkably decreased DMXAA-induced tumor necrosis, demonstrating the critical role of p38 MAPK in DMXAA-induced necrosis in vivo.
Discussion
DMXAA is a unique vascular disrupting agent with a mechanism distinct from that of other known VDAs, such as the microtubule-disrupting agent combretastatin A4-P and its derivatives. In this study, we explored the mechanism by which DMXAA disrupts the tumor vasculature. We found that DMXAA induced actin cytoskeleton reorganization in endothelial cells and TNF-α production in macrophage cells, with both effects being mediated by p38 MAPK. More importantly, these in vitro activities were translated into the in vivo antitumor effects of DMXAA. In this study, we suggest for the first time that DMXAA-induced tumor vascular disruption consists of at least two stages: an early stage (<30 min) in which tumor blood flow is rapidly reduced due to endothelial cell cytoskeleton reorganization, and a late stage marked by a sustained decrease in blood flow mediated by intratumoral TNF-α production.
Notably, both effects contribute to DMXAA-induced vascular disruption. Most importantly, p38 MAPK plays an essential role in both DMXAA-induced endothelial cell cytoskeleton reorganization and TNF-α production, and is thus a critical mediator of the antitumor activity of DMXAA.
Endothelial cells lining tumor blood vessels are the main targets for VDAs, such as combretastatin A4-P and its derivatives. Combretastatin A4-P induces rapid (Ching et al, 2002b) showed that, after administration of DMXAA at a dose of 25 mg/kg, the maximum plasma concentration of DMXAA was 530 μ M, which is sufficient for DMXAA to induce rapid actin cytoskeleton reorganization in endothelial cells. Third, the rapid reduction in tumor flow induced by DMXAA occurred much earlier than the intratumoral production of TNF-α, the rapid blood flow reduction was evident as early as 30 minutes after DMXAA administration, a time at which TNF-α production could not be detected. Thus, although we do not have direct evidence that DMXAA induces rapid endothelial cell cytoskeleton reorganization in vivo, these observations collectively indicate that the rapid shutdown of tumor blood flow induced by DMXAA results from the effect of DMXAA on endothelial cell cytoskeleton, as is the case for combretastatin A4. This may also be why DMXAA has been explored as a VDA.
A number of early studies reported that, in vivo, DMXAA induces a prompt and irreversible shutdown of blood flow that is not recovered by 24 hours, whereas the disruption in blood flow induced by combretastatin A4 disruption recovers within 24 hours (Wilson et al, 2003) . This suggests that, although DMXAA and other Given that TNF-α itself has been reported to destroy the tumor vasculature, blocking blood flow and inducing hemorrhage in tumors, and thus acting as a VDA (Zhang et al, 2009) , it is not surprising that DMXAA exhibits a stronger and longer-lasting tumor vessel-disrupting effect than combretastatin A4-P in a mouse model (Wallace et al, 2007) .
In this report, we demonstrated that p38 MAPK activation was involved in both cytoskeleton reorganization in endothelial cells and TNF-α production in macrophages; however, the mechanism by which p38 MAPK regulates actin cytoskeleton reorganization and TNF-α production remains unclear. Our results suggest that, in endothelial cells, DMXAA-induced p38 MAPK activation leads to phosphorylation of MLC, triggering the formation of actin stress fibers. Alternatively, p38 MAPK activation via MAPKAPK-2/3 may induce phosphorylation of the actin polymerization modulator HSP27 to regulate actin microfilament dynamics (Guay et al, 1997) . In addition, the fact that p38 MAPK regulated both DMXAA-induced actin cytoskeleton reorganization (data not shown) and TNF-α production in macrophages, raises the possibility that there may be a connection between actin cytoskeleton This article has not been copyedited and formatted. The final version may differ from this version. homology. p38α and p38β are ubiquitously expressed, p38γ is predominantly expressed in skeletal muscle, whereas p38δ is found in the lung, kidney, testis, pancreas, and small intestine (Kaminska, 2005) . It has been reported that murine macrophages express both p38α and p38δ, but only p38α mediates lipopolysaccharide-induced inflammatory cytokine (such as TNF-α, IL-6, sTNF-RII, and CXCL16) expression (Tang et al, 2006) . Other reports also demonstrate that p38α, but not p38β, was the major p38 isoform involved in the immune response in vivo (Beardmore et al, 2005; O'Keefe et al, 2007) . The siRNA used in our study is designed to specifically target p38α (NM_011951). The p38α siRNA significantly inhibited DMXAA-induced TNF-α production in murine macrophage Ana-1 cells, an extent similar to the p38 MAPK inhibitor SB202190, which is known to inhibit both p38α and p38β, suggesting p38α is the major p38 MAPK isoforms in mediating the DMXAA's pharmacological effect.
Consistently with the results reported recently (Sun et al, 2011), ERK1/2 was also activated in Ana-1 cells after DMXAA treatment and it participated in TNF-α production as p38 MAPK did (Fig. 2) . However, the reduction of TNF-α production induced by ERK1/2 inhibitor PD0325901 was much less than that of p38 MAPK inhibitor SB202190 (20% vs 60%), and more importantly, ERK1/2 was not involved This article has not been copyedited and formatted. The final version may differ from this version.
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Furthermore, in endothelial cells, the morphology change induced by DMXAA was not reversed by pretreatment with 20 μ M JNK inhibitor SP600125 (Fig 1A) , and in macrophage Ana-1 cells, DMXAA-induced TNF-α production was not affected by SP600125 pretreatment. Thus, we believe that p38 MAPK, but not ERK1/2 or JNK, is the key factor mediating actin cytoskeleton reorganization in tumor vascular endothelial cells and TNF-α production in macrophages, both of which contribute to DMXAA antitumor activity. This article has not been copyedited and formatted. The final version may differ from this version.
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